Literature DB >> 19081530

Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma.

Banke Agarwal1, Olivia J Ludwig, Brian T Collins, Cherise Cortese.   

Abstract

BACKGROUND & AIMS: Serial analysis of gene expression has helped identify several proteins that are expressed differentially in pancreatic cancer and are highly sensitive and specific for pancreatic adenocarcinoma. We evaluated if the diagnostic accuracy of pancreatic cancer from endoscopic ultrasound (EUS)-fine-needle aspiration (FNA) can be improved by combined evaluation of cytology and immunostaining with these markers.
METHODS: This study involved the use of archived specimens from patients treated at Saint Louis University Hospital from 2002 to 2006. We identified 5 protein markers that appeared most promising from published literature. We sequentially evaluated immunostaining with these markers in (1) surgical resection specimens, (2) cell blocks from EUS-FNA, and (3) direct smears of EUS-FN aspirates. Finally, we performed a combined evaluation of cytology and immunostaining in direct smears that were difficult to interpret and required a second consultative cytologic opinion.
RESULTS: In resection specimens, the majority of pancreatic adenocarcinomas expressed all 5 markers but fascin, maspin, and carcinoembryonic antigen-related cell adhesion molecule 6 also were expressed abnormally in normal pancreata and in chronic pancreatitis. Further evaluation therefore was limited to the other 2 markers: mesothelin and 14-3-3sigma. It was feasible and useful to perform immunostaining in cell blocks and direct smear for diagnosing pancreatic cancer. In cases requiring a second cytologic consultation, a combined evaluation of cytologic morphology and immunostaining had 90% accuracy for a pancreatic adenocarcinoma diagnosis.
CONCLUSIONS: In conclusion, immunostaining with newer protein markers is feasible in EUS-FNA specimens and can assist cytopathologists in diagnosing pancreatic cancer. Among the currently available protein immunomarkers, a combination of mesothelin and 14-3-3sigma seems most promising, but needs to be validated in prospective studies before routine clinical use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081530     DOI: 10.1016/j.cgh.2008.08.010

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

Review 1.  The role of actin bundling proteins in the assembly of filopodia in epithelial cells.

Authors:  Seema Khurana; Sudeep P George
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

2.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

4.  Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis.

Authors:  Lin Zhu; Yiling Liu; Guangyuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

5.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

6.  Imaging of pancreatic cancer: An overview.

Authors:  Pavan Tummala; Omer Junaidi; Banke Agarwal
Journal:  J Gastrointest Oncol       Date:  2011-09

Review 7.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

8.  Small and potentially resectable focal pancreatic lesions noted on CT/MRI scans in nonjaundiced patients: likelihood of neoplasia and utility of EUS.

Authors:  Naveen B Krishna; Pavan Tummala; Christopher D Mehan; Amith V Reddy; Jeremy A Hartman; Banke Agarwal
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

9.  Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel.

Authors:  Asif Ali; Victoria Brown; Simon Denley; Nigel B Jamieson; Jennifer P Morton; Colin Nixon; Janet S Graham; Owen J Sansom; C Ross Carter; Colin J McKay; Fraser R Duthie; Karin A Oien
Journal:  BMC Clin Pathol       Date:  2014-07-23

10.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Cytojournal       Date:  2014-06-02       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.